

# 2009 Milestones

During 2009, we delivered significant improvements across every facet of our business, from research and development to sales and finance, enabling us to provide patients with more innovative, effective therapies and our shareholders with sustainable returns.

## Four new products launched

- **Cimzia**<sup>®</sup>: U.S. and Europe launch for rheumatoid arthritis
- **Vimpat**<sup>®</sup>: U.S. launch for epilepsy
- **Neupro**<sup>®</sup>: Europe launch for restless legs syndrome and re-introduction for Parkinson's disease
- **Toviaz**<sup>®</sup>: U.S. launch (by Pfizer) for overactive bladder

## Five compounds in our pipeline progressed

- **Brivaracetam**: Phase III results in epilepsy
- **Keppra**<sup>®</sup> **XR**: Phase III results in epilepsy monotherapy
- **Xyrem**<sup>®</sup>: Phase III results in fibromyalgia
- **Epratuzumab**: Phase IIb results in systemic lupus erythematosus
- **CDP785 I**: moved to Phase II for fracture healing and post-menopausal osteoporosis

## Five regulatory approvals

- **Cimzia**<sup>®</sup>: U.S. approval for rheumatoid arthritis
- **Cimzia**<sup>®</sup>: EU approval for rheumatoid arthritis
- **Neupro**<sup>®</sup>: EU approval for restless legs syndrome
- **Neupro**<sup>®</sup>: EU approval to re-launch for Parkinson's disease
- **Keppra**<sup>®</sup>: EU approval for epilepsy in infants and young children

## Revenue and REBITDA as expected

- Revenue of € 3 116 million
- Recurring EBITDA of € 698 million
- Net profit of € 513 million

## 108 000 new patients treated with new products at year end 2009

- 9 000 patients treated with Cimzia®
- 46 000 patients treated with Vimpat®
- 53 000 patients treated with Neupro®

## Debt successfully re-financed

- € 1.5 billion revolving credit facility
- € 750 million retail bonds, due 2014
- € 500 million convertible bonds, due 2015
- € 500 million institutional bonds, due 2016
- Lender base diversified
- Maturity profile improved
- Old debt paid down

## New partnerships forged

- Pre-clinical oncology projects 'incubated' with Wilex AG
- Co-marketing in Germany expanded with Novartis AG
- Cimzia® commercialisation agreement for Brazil with AstraZeneca plc
- Joined NeuroAllianz consortium
- On-line community for epilepsy patients begun with PatientsLikeMe

## Organisation focused

- € 150 million re-allocated to Cimzia®, Vimpat®, Neupro®
- Geographical markets prioritised
- Non-strategic emerging markets divested
- Pre-clinical oncology products 'incubated'
- New research facility opened in the U.K.
- Workforce reduced by 22%
- Operating expenses reduced by 15%
- Cost of sales reduced by 9%